Use of fertility drugs and risk of uterine cancer: Results from a large danish population-based cohort study

American Journal of Epidemiology

Volumn 170, Issue 11, 2009, Pages 1408-1414

  Jensen, Allan ^a   Sharif, Heidi ^a   Kjaer, Susanne K ^a,b  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Clomiphene; Cohort studies; Denmark; Fertility agents; Gonadotropins; Infertility; Uterine neoplasms

Indexed keywords

CHORIONIC GONADOTROPIN; CLOMIFENE; FOLLITROPIN; GONADORELIN DERIVATIVE; HUMAN MENOPAUSAL GONADOTROPIN; ORAL CONTRACEPTIVE AGENT;

CANCER; COHORT ANALYSIS; DRUG; FERTILITY; HORMONE; INFERTILITY; REPRODUCTIVE DISORDER; RISK FACTOR;

ADULT; AGED; ARTICLE; CANCER REGISTRY; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; DENMARK; FEMALE; HUMAN; INFERTILITY; INFERTILITY THERAPY; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; OVULATION INDUCTION; PARITY; POPULATION RESEARCH; RISK ASSESSMENT; RISK FACTOR; UTERUS CANCER;

ADULT; AGED; CHORIONIC GONADOTROPIN; CLOMIPHENE; COHORT STUDIES; CONFIDENCE INTERVALS; DENMARK; FEMALE; FERTILITY AGENTS, FEMALE; GONADOTROPINS; HUMANS; MIDDLE AGED; PARITY; PREGNANCY; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; UTERINE NEOPLASMS; YOUNG ADULT;

DENMARK; EURASIA; EUROPE; NORTHERN EUROPE; SCANDINAVIA;

EID: 70849090744     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwp290     Document Type: Article

References (36)

1. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci. 2001;943:296-315.
2. Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol. 1992; 167(5):1317-1325.
3. Mogren I, Stenlund H, Högberg U. Long-term impact of reproductive factors on the risk of cervical, endometrial, ovarian and breast cancer. Acta Oncol. 2001;40(7):849-854.
4. Parazzini F, Negri E, La Vecchia C, et al. Role of reproductive factors on the risk of endometrial cancer. Int J Cancer. 1998; 76(6):784-786.
5. van Leeuwen FE, Rookus MA. The role of exogenous hormones in the epidemiology of breast, ovarian and endometrial cancer. Eur J Cancer Clin Oncol. 1989;25(12):1961-1972.
6. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85(2):304-313.
7. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without pro-gestins. J Natl Cancer Inst. 1999;91(13):1131-1137 (Pubitemid 29330551)
8. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351(9114):1451-1467.
9. Senkus-Konefka E, Konefka T, Jassem J. The effects of tamoxifen on the female genital tract. Cancer Treat Rev. 2004; 30(3):291-301.
10. Sovino H, Sir-Petermann T, Devoto L. Clomiphene citrate and ovulation induction. Reprod Biomed Online. 2002;4(3): 303-310.
11. Fishel S, Jackson P. Follicular stimulation for high tech pregnancies: are we playing it safe? BMJ. 1989;299(6694): 309-311.
12. Brinton L. Long-term effects of ovulation-stimulating drugs on cancer risk. Reprod Biomed Online. 2007;15(1):38-44.
13. Doyle P, Maconochie N, Beral V, et al. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod. 2002;17(8):2209-2213.
14. Dor J, Lerner-Geva L, Rabinovici J, et al. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril. 2002;77(2):324-327.
15. Venn A, Watson L, Lumley J, et al. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet. 1995;346(8981):995-1000.
16. Venn A, Watson L, Bruinsma F, et al. Risk of cancer after use of fertility drugs with in-vitro fertilisation.Lancet.1999;354(9190): 1586-1590.
17. Potashnik G, Lerner-Geva L, Genkin L, et al. Fertility drugs and the risk of breast and ovarian cancers: results of a long-term follow-up study. Fertil Steril. 1999;71(5):853-859.
18. Ron E, Lunenfeld B, Menczer J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1987;125(5): 780-790.
19. Modan B, Ron E, Lerner-Geva L, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol. 1998;147(11): 1038-1042.
20. Althuis MD, Moghissi KS, Westhoff CL, et al. Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol. 2005;161(7):607-615.
21. Calderon-Margalit R, Friedlander Y, Yanetz R, et al. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol. 2009;169(3):365-375.
22. Silva Idos S, Wark PA, McCormack VA, et al. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. Br J Cancer. 2009;100(11):1824-1831.
23. Benshushan A, Paltiel O, Brzezinski A, et al. Ovulation induction and risk of endometrial cancer: a pilot study. Eur J Obstet Gynecol Reprod Biol. 2001;98(1):53-57.
24. Jensen A, Sharif H, Frederiksen K, et al. Use of fertility drugs and risk of ovarian cancer: Danish population based cohort study. BMJ. 2009;338:b249. (DOI: 10.1136/bmj.b249).
25. Jensen A, Sharif H, Svare EI, et al. Risk of breast cancer after exposure to fertility drugs: results from a large Danish cohort study. Cancer Epidemiol Biomarkers Prev. 2007;16(7):1400-1407.
26. Hannibal CG, Jensen A, Sharif H, et al. Risk of thyroid cancer after exposure to fertility drugs: results from a large Danish cohort study. Hum Reprod. 2008;23(2):451-456.
27. Hannibal CG, Jensen A, Sharif H, et al. Malignant melanoma risk after exposure to fertility drugs: results from a large Danish cohort study. Cancer Causes Control. 2008;19(7): 759-765.
28. Barlow WE, Ichikawa L, Rosner D, et al. Analysis of case-cohort designs. J Clin Epidemiol. 1999;52(12):1165-1172.
29. Barlow WE. Robust variance estimation for the case-cohort design. Biometrics. 1994;50(4):1064-1072.
30. Prentice RL. A case-cohort design for epidemiological cohort studies and disease prevention trials. Biometrika. 1986;73: 1-11.
31. Rose PG. Endometrial carcinoma. N Engl J Med. 1996;335(9): 640-649.
32. Hack M, Brish M, Serr DM, et al. Outcome of pregnancy after induced ovulation. Follow-up of pregnancies and children born after clomiphene therapy. JAMA. 1972;220(10):1329-1333.
33. Nakamura Y, Ono M, Yoshida Y, et al. Effects of clomiphene citrate on the endometrial thickness and echogenic pattern of the endometrium. Fertil Steril. 1997;67(2):256-260.
34. Goldstein SR, Siddhanti S, Ciaccia AV, et al. A pharmacological review of selective oestrogen receptor modulators. Hum Reprod Update. 2000;6(3):212-224.
35. Jensen A, Sharif H, Olsen JH, et al. Risk of breast cancer and gynecologic cancers in a large population of nearly 50,000 infertile Danish women. Am J Epidemiol. 2008;168(1):49-57.
36. Nyboe Andersen A, Gianaroli L, Nygren KG. Assisted reproductive technology in Europe, 2000. Results generated from European registers by ESHRE. Hum Reprod. 2004; 19(3):490-503